Policy & Regulation
PureTech Health reports positive Phase 1b data for LYT-200 in MDS and AML
22 April 2026 - Biotherapeutics company PureTech Health plc reported on Wednesday that its founded entity Gallop Oncology reported positive topline Phase 1b data for LYT-200 in relapsed/refractory hig...
European Commission approves Ojemda as first targeted therapy for relapsed paediatric low-grade glioma
22 April 2026 - French biopharmaceutical company Ipsen (Euronext Paris:IPN) (ADR:IPSEY) announced on Wednesday that the European Commission has granted conditional marketing authorisation for Ojemda (...
Solvonis Therapeutics appoints Water Tower Research to strengthen US market positioning
22 April 2026 - Biopharmaceutical company Solvonis Therapeutics plc (LSE: SVNS) announced on Wednesday that it has appointed US-based research and investor engagement firm Water Tower Research LLC to ...
Ondine Biomedical abstracts selected for 2026 World Congress on Infectious Diseases
22 April 2026 - Ondine Biomedical Inc (LON: OBI), a provider of photodisinfection-based therapies, announced on Wednesday that it has secured acceptance of two abstracts for poster presentation at the...
hVIVO secures Phase III human challenge trial contract with ILiAD Biotechnologies
22 April 2026 - Clinical development partner hVIVO plc (AIM: HVO) announced on Wednesday that it has signed a contract with ILiAD Biotechnologies Inc to conduct a pivotal Phase III human challenge tri...
FDA expands approval of Sanofi's Tzield for early-stage type 1 diabetes in young children
22 April 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Wednesday that the US Food and Drug Administration (FDA) has approved an expanded indication for Tz...